Harmonising Regulatory Submissions for Pharmaceutical Products Across ASEAN Markets

Key Takeaways

Harmonisation with the ASEAN Common Technical Dossier (ACTD) helps standardise formats, but local variations still exist.
Different pharmaceutical markets in ASEAN have different review timelines. Strategic sequencing matters.
A centralised approach strengthens efficiency, especially for multi-country pharma dossier management.
Experienced partners offering regulatory and advisory services are vital for long-term compliance.

Why Harmonisation Matters Now

The ASEAN pharmaceutical market is one of the fastest-growing globally, offering strong potential for companies that can expand efficiently. Yet, without a harmonised regulatory strategy, firms often face costly delays, repeated work, and regulatory hurdles. Moreover, each country has its own processes, and adapting separately to them can stretch timelines into years.

This is why a well-planned approach using the ACTD framework is essential. By aligning submissions from the outset, pharmaceutical companies can avoid repetitive work, streamline approvals, and secure a stronger competitive position in the region.

What is the ASEAN Common Technical Dossier (ACTD)?

The ACTD was developed to simplify submissions across the region by providing a unified format for regulatory filings. While it draws inspiration from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the ACTD is streamlined and adapted for ASEAN markets.

The ACTD consists of four parts:

Part I: Administrative and Product Information
Part II: Quality
Part III: Nonclinical
Part IV: Clinical

By aligning submissions with ACTD, companies can prepare a single master file and adapt only the necessary sections to meet local requirements. This not only reduces effort but also ensures greater consistency across regional filings.

What are the Challenges in Local Variations?

Pharmaceutical capsules being manufactured.

Despite the adoption of the ACTD framework, individual ASEAN pharmaceutical authorities continue to enforce their own requirements. These local variations can complicate the submission process and, if not addressed early, cause significant delays. For example:

Indonesia: According to the National Agency of Drug and Food Control (NADFC), all label information must be written in Bahasa Indonesia. Exceptions include export-only products and specific cases.
Thailand: Any pharmaceutical product, whether manufactured domestically, imported, or ordered in, must comply with Thailand’s Drug Act B.E. 2510 (1967) and its subsequent amendments.

These country-specific requirements can add months to the process if not planned for early. Engaging pharma regulatory services that recognise these local nuances can help your submissions move forward without avoidable setbacks.

Discrepancies in Timelines and Review Processes

Pharmaceutical approval timelines may also vary widely across ASEAN countries:

Singapore: The Health Sciences Authority (HSA) outlines timelines of around 12–15 months for a full new drug application.
Malaysia: According to NPRA guidelines, generic applications generally take about 12–18 months for evaluation.
Indonesia: Drug registration can range from 12 to 24 months, with biologics often on the longer end.

These differences directly impact resource planning and manufacturing schedules. Strategic sequencing of submissions becomes essential, enabling companies to avoid bottlenecks and better optimise internal teams.

Role of Local Agents and Representatives

Most ASEAN countries require pharmaceutical companies to appoint an in-country representative to manage submissions and post-approval responsibilities. These agents handle regulator queries, coordinate inspections, and oversee pharmacovigilance.

Choosing the right partner is critical. A knowledgeable consultant not only ensures compliance with guidelines but also understands local nuances. In Singapore, for example, pharmaceutical companies should engage experts for HSA registration and regulatory support, preventing costly delays and streamlining the approval process.

What are the Benefits of Centralised Dossier Management?

Centralised dossier management allows companies to maintain a single master file structured around ACTD guidelines, updating only the sections required to meet local variations. This approach not only streamlines preparation but also improves regulatory consistency across the region.

Key benefits include:

Efficiency: Reduces duplication of work by creating one master dossier for adaptation.
Consistency: Minimises discrepancies across harmonised pharma submissions in different ASEAN markets.
Lifecycle Management: Simplifies renewals, post-approval variations, and safety updates across multiple jurisdictions simultaneously.

This helps align resources with varying review timelines and regulatory expectations, reducing both costs and compliance risks.

Recent and Upcoming Developments in ASEAN

In recent years, the ASEAN Pharmaceutical Product Working Group has intensified its efforts to bring greater alignment across member states. Ongoing initiatives include updates to ACTD standards, harmonisation of stability testing standards, and closer coordination of review requirements. While these changes help reduce discrepancies, companies must stay alert to avoid compliance gaps.

At The Reg Consultants (TRC), our team of regulatory affairs consultants actively monitors these developments, enabling clients to adapt quickly and stay ahead of changes across ASEAN markets.

Conclusion

Harmonising your pharmaceutical submissions across ASEAN countries has become a strategic advantage. By staying aligned with ACTD regulations and anticipating local variations, companies can shorten approval timelines, reduce costs, and streamline regional launches.

At The Reg Consultants, we specialise in helping companies navigate these complexities. From dossier preparation to in-country support, our team is here to ensure that your strategy is both compliant and efficient. Work with our experts to accelerate approvals and secure lasting success across the region.

Back To Blog